Rigel Pharmaceuticals, Inc.
RIGL · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $179,278 | $116,882 | $120,242 | $149,236 |
| % Growth | 53.4% | -2.8% | -19.4% | – |
| Cost of Goods Sold | $18,647 | $7,110 | $1,749 | $1,083 |
| Gross Profit | $160,631 | $109,772 | $118,493 | $148,153 |
| % Margin | 89.6% | 93.9% | 98.5% | 99.3% |
| R&D Expenses | $23,380 | $24,522 | $60,272 | $65,237 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $113,059 | $105,741 | $112,451 | $91,891 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $1,320 | $3,521 |
| Operating Expenses | $136,439 | $130,263 | $174,043 | $160,649 |
| Operating Income | $24,192 | -$20,491 | -$55,550 | -$12,496 |
| % Margin | 13.5% | -17.5% | -46.2% | -8.4% |
| Other Income/Exp. Net | -$5,826 | -$4,600 | -$3,023 | -$4,813 |
| Pre-Tax Income | $18,366 | -$25,091 | -$58,573 | -$17,309 |
| Tax Expense | $881 | $0 | $0 | $605 |
| Net Income | $17,485 | -$25,091 | -$58,573 | -$17,914 |
| % Margin | 9.8% | -21.5% | -48.7% | -12% |
| EPS | 0.99 | -1.44 | -3.4 | -1.1 |
| % Growth | 168.7% | 57.6% | -209.1% | – |
| EPS Diluted | 0.99 | -1.44 | -3.4 | -1.1 |
| Weighted Avg Shares Out | 17,579 | 17,401 | 17,241 | 17,049 |
| Weighted Avg Shares Out Dil | 17,687 | 17,401 | 17,241 | 17,049 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2,092 | $2,272 | $684 | $47 |
| Interest Expense | $7,918 | $6,872 | $3,707 | $4,860 |
| Depreciation & Amortization | $2,228 | $1,238 | $998 | $1,162 |
| EBITDA | $28,512 | -$16,981 | -$53,868 | -$11,287 |
| % Margin | 15.9% | -14.5% | -44.8% | -7.6% |